Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma (Q44955205)

7 December 2017

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma (English)

1 reference

7 December 2017

Brian I Rini

1

1 reference

7 December 2017

Vivian Weinberg

2

1 reference

7 December 2017

Vanessa Shaw

3

1 reference

7 December 2017

Janet Scott

4

1 reference

7 December 2017

Robert Bok

5

1 reference

7 December 2017

John W Park

6

1 reference

7 December 2017

Eric J Small

7

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

7 December 2017

1 reference

7 December 2017

101

1 reference

7 December 2017

1

1 reference

7 December 2017

90-95

1 reference

UCN-01, a selective inhibitor of protein kinase C from Streptomyces.

7 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Detection and characterization of carcinoma cells in the blood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20313

7 January 2021

Identifiers

DOI

10.1002/CNCR.20313

1 reference

7 December 2017

1 reference